FindTrial
Sign In

Implication of Cardiac Shock Wave Therapy on Coronary Heart Disease

Implication of Cardiac Shock Wave Therapy on Coronary Heart Disease: A Prospective Randomized Double-blind Control Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009777
Enrollment
Unknown
Registered
2016-11-08
Start date
2016-11-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

placebo shock wave group:placebo shock wave
Shock Wave group:Cardiac shock wave

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Multiple or diffused coronary artery stenosis by coronary angiography and not candidate for PCI or CABG; 2. Myocardial ischemia and/or cardiac dysfunction by objective exams; 3. Angina and/or heart failure could not be control after optimal treatment for coronary artery disease; 4. LVEF is above 30%; 5. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Acute myocardial infarction; 2. Within one month after PCI or CABG; 3. Heart transplant patient; 4. Prosthetic valve patient; 5. Uncontrolled heart failure with LVEF less than 30%; 6. Severe arrhythmia; 7. Pacemaker implantation patient; 8. Infective endocarditis; 9. Severe chronic obstructive pulmonary disease patient; 10. Pregnant or nursing patient; 11. Silicone breast forms patient; 12. Chest tumor patient; 13. Participant in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Ischemic area;—

Countries

China

Contacts

Public ContactHE QING

Beijing Hospital

heqingli2001@126.com+86 13901601188

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026